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ABSTRACT
The stromal microenvironment controls response to injury and inflammation, and 
is also an important determinant of cancer cell behavior. However, our understanding 
of its modulation by miRNA (miR) and their respective targets is still sparse. Here, we 
identified the miR-25-93-106b cluster and two new target genes as critical drivers for 
metastasis and immune evasion of cancer cells. Using miR-25-93-106b knockout mice 
or antagomiRs, we demonstrated regulation of the production of the chemoattractant 
CXCL12 controlling bone marrow metastasis. Moreover, we identified the immune 
checkpoint PD-L1 (CD274) as a novel miR-93/106b target playing a central role in 
diminishing tumor immunity. Eventually, upregulation of miR-93 and miR-106b via 
miR-mimics or treatment with an epigenetic reader domain (BET) inhibitor resulted 
in diminished expression of CXCL12 and PD-L1. These data suggest a potential new 
therapeutic rationale for use of BET inhibitors for dual targeting of cancers with strong 
immunosuppressive and metastatic phenotypes.
INTRODUCTION
The bone marrow (BM) stromal niche harbors and 
controls hematopoietic stem cells (HSC) [1], and also plays 
a critical role in the recruitment and survival of normal 
and neoplastic cells via production of chemoattractants. 
Still, our understanding of the epigenetic regulation of the 
stromal niche during homeostasis and in response to injury 
or tumorigenesis remains very limited [1, 2]. Therefore, 
we studied the role of microRNA (miR) in regulating 
the stromal niche. MiR are short, non-coding RNAs 
regulating target mRNAs. Base pair interactions between 
miR and target mRNAs within the 3’UTR (untranslated 
region) result in the degradation of the target mRNAs or 
modulation of their translation. Using tissue ischemia as 
a model for activating the BM niche, we found that the 
miR-25-93-106b cluster was most prominently upregulated 
encouraging us to validatein silico predicted targets of this 
cluster, i.e. the chemokine CXCL12 (stromal cell-derived 
factor-1; SDF-1), ligand for the chemokine receptor 
CXCR4, and the immune modulator CD274 (programmed 
cell death ligand-1; PD-L1), which binds to CD279 (PD-1).
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CXCL12 is a key attraction and retention signal for 
stem cells including cancer stem cells [3, 4] via activation 
of its receptor CXCR4. Cells expressing strongly CXCL12 
in the stromal niche are mostly endothelial cells and 
perivascular mesenchymal stromal cell populations 
including cancer-associated fibroblasts [5, 6], and 
CXCL12 levels are variably modulated in response to 
local or remote pro-inflammatory stimuli [7–9]. The PD-
L1 – PD-1 signaling pathway efficiently inhibits T-cell 
activation [10, 11] and growing evidence demonstrates 
that blockade of PD-1 or its ligand PD-L1 significantly 
enhances anti-tumor immunity resulting in durable tumor 
regression in a sizable fraction of patients with advanced 
cancers [12]. Therefore, advancing our understanding 
of the underlying regulatory mechanisms for these two 
critical pathways may also provide the basis for the 
development of more efficient cancer treatments.
RESULTS
Upregulation of the miR-25-93-106b cluster in 
the BM stromal niche in response to remote 
tissue insult
To study the role of miR in the regulation of the 
stromal niche, we examined changes in miR expression in 
BM stromal cells in response to tissue insult (Figure 1A). 
Considering that many cancers are poorly vascularized 
and invested with inflammation [13], we used two 
reproducible and hypothesis-generating model systems, 
unilateral hind limb ischemia and total body irradiation 
(TBI), which can also be applied to respective knockout 
mice in a timely fashion. First, we analyzed the BM stroma 
in the contralateral, non-ischemic hind limb of the hind 
limb ischemia model (Supplementary Figure 1A–1D). We 
found all three members of the miR-25-93-106b cluster 
to be consistently increased (Figure 1A). Upregulation 
of miR-25, 93, and 106b was confirmed by qRT-PCR 
in sorted CD45– BM cells and CD45–CD140a+SCA-1+ 
mesenchymal progenitor cells, respectively (Figure 1B) 
[14]. In line with the hypothesis that miR-25-93-106b 
is important for tissue regeneration, induction of hind 
limb ischemia or myocardial infarction in miR-25-
93-106b KO mice resulted in a significantly reduced 
limb perfusion and larger infarct sizes, respectively 
(Supplementary Figure 1A-1E). In addition, miR-25-93-
106b KO mice undergoing myocardial infarction showed 
a strong desmoplastic response in line with an increased 
fibroblastoid colony-forming activity detected in miR-25-
93-106b KO mice (Supplementary Figure 4). Consistently, 
in pancreatic tumors as a prototypic cancer with extensive 
desmoplasia, we also found a suppression of the miR-
25-93-106b cluster in stromal cells relative to the cancer 
cells (Supplementary Figure 2A). These data were also 
further confirmed by assessment of freshly isolated and 
sorted stromal and cancer cells by qRT-PCR showing 
lower expression of miR-93 and miR-106b in stromal cells 
than cancer cells (Supplementary Figure 10). In addition, 
we performed in situ hybridization (ISH) for miR-106b 
visualizing miR-106b expression in primary pancreatic 
cancer and liver metastasis, thereby confirming expression 
in both stromal cells and cancer cells as well as inverse 
target regulation (Supplementary Figure 11).
Enhanced recruitment and invasion of bone 
marrow cells upon downregulation of miR-
93/106b in the stromal niche
Tissue repair and tumor development are 
accompanied by the influx of various cells including BM 
cells (BMC). We used DiD-labeled HSC-containing BMC 
freshly derived from WT mice to study their capacity to 
home to the BM of irradiated miR-25-93-106b KO vs. WT 
mice (Figure 2A/2B). We observed that DiD+ WT BMC 
were more efficiently recruited to the BM stroma of miR-
25-93-106b KO mice as compared to WT BM suggesting 
that miR-25-93-106b KO mice produce higher levels of 
chemoattractants following tissue insult, i.e. total body 
irradiation (TBI). To validate individual cluster members 
as crucial for the observed phenotype, we studied the 
invasion of WT BMC towards CD45– WT BM-derived 
mesenchymal stem cells (WT-MSC) that were pre-treated 
with control or antagomiR for miR-25, 93, and 106b. We 
found enhanced invasion/migration through the Matrigel™ 
layer for WT-MSC treated with antagomiR for miR-93 and 
106b, but not for miR-25 (Figure 2C/Figure 5E).
To further corroborate these findings, we used a 
distinct setting where mice were exposed to TBI followed 
by BM transplantations using low numbers (105) of donor 
Katushka+ WT BMC so that successful engraftment was 
critically dependent on a proficient BM niche. As opposed 
to remote tissue ischemia, TBI suppressed the expression 
of the miR-25-93-106b cluster (Supplementary Figure 
2B). Survival of mice following WT BM transplantation 
was almost two-fold higher for miR-25-93-106b KO 
recipients as compared to WT recipients (Figure 2D). 
This was in line with increased numbers of Katushka+ 
WT BM cells in the BM of miR-25-93-106b KO recipient 
mice (Figure 2E) suggesting that more WT BM cells had 
migrated to the TBI-injured BM of miR-25-93-106b KO 
mice. In line with these data, WT CD45+C-KIT+ BMC 
showed enhanced invasiveness when migrating towards 
adherently growing miR-25-93-106b KO MSC relative to 
WT MSC cell layers (Supplementary Figure 2C).
Reverse experiments using miR-25-93-106b KO 
BM cells transplanted into WT recipients resulted in 
impaired survival of the mice as compared to WT mice 
transplanted with WT BM cells (Supplementary Figure 
3A). The impaired BM reconstitution by KO BM could 
also be demonstrated by reduced levels of platelet-
producing megakaryocytes and neutrophilic granulocytes 
resulting in prolonged bleeding times and neutropenia 
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Figure 1: Ischemia-induced up-regulation of miR-25-93-106b in the bone marrow (BM) stromal niche. A. MiRNA array 
for CD45– BM stromal cells following sham surgery (S) or ischemia induction (I). Grey background: most prominently upregulated miR, 
red: members of the miR-25-93-106b cluster (left). Validation by qRT-PCR; n=5-6, * p<0.05 (right panel). B. Gating strategy (left) and 
quantification (right) of CD45–CD140a+SCA-1+ mesenchymal progenitor cells. Quantification by qRT-PCR; n=3-4, * p<0.05.
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Figure 2: Enhanced recruitment and invasion of bone marrow cells upon downregulation of miR-93/106b in the 
stromal niche. A. In vivo homing of DiD-labeled BMC to the irradiated BM of WT vs miR-25-93-106b KO mice, n=4, * p<0.05 (left). 
Representative flow cytometry (right). B. Ex vivo confocal analysis of irradiated WT sternal BM 48 hours after i.v. injection of DiD+ BM 
cells (red). Vascularization is identified by lectin staining (green). Homing of individual DiD+ BM cells is indicated (arrows). C. In vitro 
invasion of BMC towards WT-MSC in the presence or absence of miR-25/93/106b antagomiR. n=7, * p<0.05 for miR-25/93/106b antagomir 
treatment versus control antagomir. D. Kaplan-Meier survival curves of recipient WT vs KO mice following WT BM transplantation; n=14, 
* p<0.05. E. Homing of Kat+ WT BM cells to the BM of irradiated WT vs KO mice; n=3, * p<0.05 (left). Representative flow cytometry 
is shown (right).
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(Supplementary Figure 3B) as well as reduced levels 
of granulocyte and megakaryocyte progenitors in 
in vitro colony-forming unit (CFU) formation assays 
(Supplementary Figure 3C). Interestingly, while myeloid 
progenitors were also reduced, fibroblast progenitors 
assessed as fibroblastoid CFU (CFU-F) were increased 
in the BM of miR-25-93-106b KO mice, which may 
at least in part rationalize the enhanced desmoplastic 
response in these mice (Supplementary Figure 1E) that 
is also characteristic of many tumors [13]. Consistently, 
fibroblast activation protein (FAP)+CD45– fibroblasts 
and FAP+CD45+ fibrocytes were both increased in the 
BM and peripheral blood of miR-25-93-106b KO mice 
(Supplementary Figure 4A/4B). About 60% of CD45+ 
colony-derived cells were CD11b+, of which ~3% were 
FAP+. Importantly, while peripheral blood-derived 
fibroblastoid CFU from WT mice exhibited increased 
numbers of CD45–C-KIT+ vascular progenitors in response 
to ischemia, miR-25-93-106b KO mice showed impaired 
mobilization of vascular progenitors into the peripheral 
blood (Supplementary Figure 4C).
Enhanced recruitment and invasion of cancer 
cells upon downregulation of miR-93/106b
To validate these findings in the context of cancer 
metastasis, we next studied the homing of human Nalm-
6 cancer cells to the BM as a crucial step in metastasis, 
which still represents a primary reason for cancer-
associated lethality. DiD-labeled Nalm-6 cells were 
intravenously injected into irradiated miR-25-93-106b KO 
and WT mice, respectively, and the BM was examined 6 
hours afterward showing increased homing to MiR-25-
93-106b KO BM (Figure 3A). These data were confirmed 
by ex vivo migration assays employing explanted and slit 
bones of irradiated miR-25-93-106b KO or WT mice, 
placed at one end of a flow chamber, while DiD+ Nalm-
6 cells were placed at the other end, both connected via 
a microfluidic channel. We found increased numbers of 
Nalm-6 cells migrating towards miR-25-93-106b KO bone 
fragments (Figure 3B). DiD+ Nalm-6 cells also migrated 
more efficiently towards irradiated miR-25-93-106b KO 
BM-derived MSC as compared to WT MSCs (Figure 3C).
Identification of potentially relevant targets for 
the miR-25-93-106b cluster
To interrogate the large list of potentially relevant 
targets modulated by miR-25-93-106b, we isolated 
CD45– BM stromal cells from miR-25-93-106b KO vs. 
WT mice following induction of ischemia for 48 hours. 
We did not only study established targets of the mir-25-
93-106b cluster i.e. p21 [15], integrin b8 (Itgb8) [16], 
and transforming growth factor b receptor II (Tgfbr2) 
[17], but also in silico predicted targets such as Zeb2 
(Supplementary Figure 5), Cxcl12 (Figure 4A), and Cd274 
(Figure 6A). Not unexpectedly, all above target genes, 
except Cd274 (Figure 7A), were downregulated in WT 
mice in response to tissue insult but were unleashed in 
miR-25-93-106b KO mice (Figure 4B & Supplementary 
Figure 5). For further investigation we selected CXCL12 
as an established critical regulator of stem cell homing and 
mobilization, respectively [18, 19] and PD-L1 and PD1 
as a crucial immune checkpoint with strong translational 
relevance.
The miR-25-93-106b cluster is a negative 
regulator of CXCL12
Using 3’UTR Cxcl12 luciferase assays, we first 
validated that miR-93-5P and miR-106b-5P suppressed 
luciferase activity establishing Cxcl12 as a miR-93-
5P/106b-5P target (Figure 4C). Moreover, Cxcl12 was 
downregulated in CD45– BM stromal cells of WT mice 
following tissue ischemia, while miR-25-93-106b KO mice 
showed higher baseline levels for Cxcl12 in sham-treated 
mice and lack of suppression following tissue ischemia 
(Figure 4B). These in vivo results were corroborated 
using CD45– BM cells treated ex vivo with miR-93/106b 
antagomiR demonstrating upregulation of Cxcl12 (Figure 
4D). Again we pursued TBI as a distinct modality of 
tissue injury and analyzed the bone marrow after 6 and 
24 hours for the expression of CXCL12 using confocal 
microscopy (Figure 5A/5B). During 24 hours, TBI-induced 
expression of CXCL12 protein in WT BM stromal niches, 
but CXCL12 levels were significantly higher in miR-
25-93-106b KO mice. This was confirmed by qRT-PCR 
analysis (Figure 5C) and intracellular flow cytometry for 
CXCL12 (Figure 5D). To functionally validate CXCL12 
as a chemokine that is crucial for the observed phenotype, 
we next studied WT BMC invading and migrating through 
a Matrigel™ layer towards adherently growing CD45– 
BM-derived mesenchymal stem cells (MSC). The specific 
CXCR4 antagonist AMD3465 abrogated the enhanced 
invasiveness (Figure 5E) demonstrating that the miR-
25-93-106b cluster regulates stem cell trafficking via 
CXCL12 (Figure 5F). In addition, we also corroborated 
the role of CXCL12 using CRISPR/Cas9-mediated gene 
editing to create CXCL12 knock-out cells confirming the 
role for CXCL12 in miR deficiency–induced migration 
(Supplementary Figure 8).
The miR-25-93-106b cluster targets CD274 in 
cancer cells
Next we investigated whether the miR-25-93-106b 
cluster is also involved in modulating immune tolerance, 
which is particularly important during tumor cell trafficking 
and metastasis when cancer cells are directly exposed 
without a protective tumor microenvironment. Our in silico 
prediction screen suggested that miR-106b-5P and miR-93-
5P are targeting the checkpoint inhibitor Cd274 (PD-L1) 
Oncotarget21614www.impactjournals.com/oncotarget
Figure 3: Enhanced recruitment and invasion of cancer cells upon downregulation of miR-93/106b in the stromal 
niche. A. Number of DiD+ Nalm-6 cells found in the BM of WT vs KO mice 6 hours after injection; n=4, * p<0.05. Representative flow 
cytometry (left) and quantification (right). B. Migration of DiD+ Nalm-6 cells to WT and KO BM ex vivo; n=6, * p<0.05. Representative 
confocal image (upper left), migration chamber (lower left), quantification (right). C. Migration/invasion of DiD+ Nalm-6 cells to WT and 
KO MSC following irradiation; n=4, * p<0.05.
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Figure 4: The miR-25-93-106b cluster is a negative regulator of Cxcl12. A. In silico prediction of Cxcl12 as miR-93/106b 
target by www.microrna.org. B. Cxcl12 expression of CD45–BM cells in WT vs miR-25-93-106b KO mice following sham surgery (S) or 
induction of ischemia (I); n=3, * p<0.05. C. 3’UTR Cxcl12 luciferase assay in HEK293 cells in the presence or absence of miR-93 and 
miR-106 mimics; n=9, * p<0.05. D. Cxcl12 expression in ex vivo CD45– BM cells with or without miR-93/106b antagomiR; n=5, * p<0.05.
Oncotarget21616www.impactjournals.com/oncotarget
Figure 5: The miR-25-93-106b cluster is a negative regulator of Cxcl12 in the bone marrow stromal niche. A. Ex vivo 
confocal microscopy analysis for CXCL12 expression in WT vs miR-25-93-106b KO BM cells following in vivo whole body irradiation. 
Representative images were taken 6 and 24 hours after irradiation. B. High-power confocal microscopy of CXCL12 expression in the 
BM stromal niche ex vivo. C. Cxcl12 mRNA expression was quantified by qRT-PCR 6 and 24 hours after irradiation; n=5, * p<0.05. D. 
Representative flow cytometry of intracellular CXCL12 expression in WT vs KO BM (left) and quantification; n=3, * p<0.05 (right). 
E. In vitro invasion of BMC towards WT-MSC in the presence or absence of miR-25/93/106b antagomiR. The CXCR4 antagonist AMD 
3465 was used to inhibit CXCL12/CXCR4 signaling. Control groups are replicated from Figure 2C; n=7, * p<0.05 for miR-25/93/106b 
antagomir treatment versus control antagomir, ** p<0.05 for CXCR4 antagonist treatment versus PBS control. Quantification (left) and 
schematic illustration (right). F. Role of the miR-25-93-106b cluster in the bone marrow niche. Illustration that the bone marrow niche in 
our in vitro setup is mimicked by MSC expressing CXCL12.
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(Figure 6A), but not any of the other key players expressed 
on T-cells that induce tolerance such as Pdcd-1, Ctla4, 
Ido1/2, Lag3, Tim3, Fasl, and Cd80/86 (data not shown). 
In line with this prediction, primary cancer cells also 
expressed CD274, which was further enhanced by inducing 
a more invasive phenotype using macrophage-conditioned 
medium (Figure 6B) [20]. Surprisingly, however, 
expression of CD274 was lower in the contained subset of 
cancer stem cells as compared to their more differentiated 
progenies (Supplementary Figure 6A), whereas miR-106b-
5P expression was inversely increased in cancer stem cells 
(Supplementary Figure 6B); findings that are still in line 
with previous findings for cholangiocarcinoma CSC [21]. 
Importantly, expression of CD274 was reduced in bulk 
cancer cells following treatment with miR-106b-5P and 
miR-93-5P mimics, respectively (Figure 6C). Intriguingly, 
dual inhibition of both CXCL12 and CD274 at the mRNA 
and protein level could be achieved by miR-106b-5P 
mimics (Figure 6D). Inversely, CD274 expression was 
enhanced by treatment with miR-106b-5P antagomiR 
(Supplementary Figure 6C).
The miR-25-93-106b cluster targets CD274 in 
stromal cells
In line with above findings for primary cancer 
cells, we also found that miR-25-93-106b KO mice 
bear 50% more CD274+ myeloid CD11b+ BM cells 
as compared to WT mice (Figure 7A & Supplementary 
Figure 7A/7B) and the increase is even further enhanced 
upon TBI (which reduces expression of miR-25-93-
106b). Similar or even greater differences were observed 
for the analysis of freshly isolated untreated splenocytes 
(Supplementary Figure 7C), splenocytes stimulated with 
phytohemagglutinin (PHA) to activate T cells to secrete 
IFNg as a classical inducer of PD-L1 [22] (Figure 7B), and 
monocytic myeloid-derived suppressor cells (M-MDSC) 
(Figure 7C & Supplementary Figure 7D). Sorted CD274-
expressing M-MDSC from the peripheral blood of tumor-
bearing mice showed a diminished expression of CD274 
following treatment with miR-93 mimics (Figure 7D). In 
line with these findings, freshly isolated tumor cells treated 
with miR-93-5P and miR-106b-5P mimics also exhibited 
significantly reduced expression of CD274 (Figure 6C). 
Intriguingly, these effects could be mimicked by treatment 
with inhibition of the bromodomain and extraterminal 
(BET) family of proteins, i.e. using OTX015, which 
resulted in upregulation of both miRs and subsequent 
suppression of Cd274 and Cxcl12 (Figure 7E). Similar 
data were obtained for OTX015 and the expression of 
Cd274 in primary cancer cells (Supplementary Figure 6D). 
In addition, we further confirmed the role of the miR-25-
93-106b cluster for the regulation of CD274 demonstrating 
that miR-106b deficiency partially prevented the OTX015-
induced suppression of CD274 (Supplementary Figure 9). 
Therefore, our data demonstrate that miR-93-5P and 
miR-106b-5P negatively regulate CXCL12 and CD274 
expression in both cancer cells and MDSC, and that BET 
inhibitors represent a suitable upstream modality to control 
expression of CXCL12 and CD274 via transcriptional 
regulation of the miR-25-93-106b cluster.
DISCUSSION
The BM stromal niche plays a crucial role for 
survival, maintenance, and mobilization of stem and 
progenitor cells as well as cancer (stem) cells via the 
production of chemoattractsignals such as CXCL12. 
Our results elucidate how danger signals such as remote 
ischemia and systemic total body radio-injury mediate 
signals to the stromal niche through the evolutionary 
conserved mir-25-93-106b cluster. Specifically, we 
identified that the cluster members miR-93 and 106b 
are essential regulators of the BM stromal compartment 
for cell homing and mobilization, respectively, through 
targeting CXCL12. Our data were functionally validated 
by transplanting normal BM cells into secondary hosts, 
but interestingly, we also found that the mir-25-93-106b 
cluster altered the receptiveness of the BM for metastatic 
cancer cells via the same mechanism. Moreover, we 
provide conclusive evidence that the immune modulator 
CD274 is another novel target of miR-93/106b, not 
only in BM (stromal) cells but also in M-MDSC and 
primary cancer cells. Thus, our data suggest that miR-
93/106b mimics or their transcriptional modulation by 
bromodomain inhibition could be used for dual targeting 
of cancers with a strong immunosuppressive and 
metastatic phenotype.
To date, few miR such as miR-23a and miR-886-
3p have been implicated in the regulation of CXCL12 in 
BM stromal cells in vitro [23, 24]. Also, cancer cells and 
cancer-associated stromal cells showed down-regulation 
of miR-126, thus enhancing the release of CXCL12 and 
subsequently recruiting MSCs to further promote tumor 
cell invasion and metastasis [25]. Importantly, we found 
that the actual response of the bone marrow stromal 
niche was dependent on the type of insult. In response 
to the induction of remote tissue injury, i.e. induction 
of ischemia, as found in many cancers, we observed 
members of the miR-25-93-106b cluster to be strongly 
upregulated resulting in downregulation of CXCL12 in 
the BM stromal niche. The diminishment of the CXCL12 
gradient in the BM niche resulted in the release of stem 
and progenitor cells and their subsequent mobilization 
into the peripheral blood and traveling to the site of injury 
[8]. In contrast, ionizing radiation-induced oxidative 
stress had previously been demonstrated to alter miR in 
a time- and dose-dependent manner [26, 27]. Specifically, 
expression of miR-106b was downregulated in response to 
higher doses of irradiation [27]. Moreover, irradiation had 
been reported to upregulate CXCL12, an effect that was 
reportedly further enhanced by hypoxia [28]. Consistently, 
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Figure 6: Regulation of the miR-25-93-106b target CD274 in pancreatic cancer cells. A. In silico prediction of CD274 as a 
target of miR-93 and miR-106b. B. Expression of CD274 in pancreatic cancer cells in the absence or presence of macrophage-conditioned 
medium (CM). C. CD274 expression as determined by flow cytometry in freshly isolated murine primary PDAC tumors in the presence 
of miR-93 or miR-106b mimics 20 hours after transfection; n=3, * p<0.05. D. Dual inhibition of Cxcl12 and CD274 expression in freshly 
isolated murine primary PDAC tumors as determined by flow cytometry and qRT-PCR, n=4-5, * p<0.05.
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we demonstrate that total body irradiation resulted in a 
downregulation of the miR-25-93-106b cluster followed 
by an increase in CXCL12.
An important target population for CXCL12-
mediated recruitment and signaling are CXCR4+ cancer 
stem cells, which are mostly found in the invasive front 
and are essential for metastasis [3, 29]. The BM stromal 
niche provides a favorable environment for circulating 
tumor settlement and growth, in which CXCL12 plays 
a critical role in tumor cell recruitment and lodgment. 
CXCL12 neutralization in vivo within BM niches 
renders the BM less receptive and thus reduced homing, 
Figure 7: MiR-93/106b regulates CD274 and CXCL12 expression. A. CD274 expression in CD11b+ BM cells as determined 
by flow cytometry 6 hours following total body irradiation. Quantification of data with untreated WT set as 100%; n=3-5, * p<0.05. B. 
Expression of CD274 in splenocytes following PHA activation; n=4, * p<0.05. C. Quantification of CD274 expression in sorted M-MDSC 
derived from WT vs miR-25-93-106b KO mice using qRT-PCR; n=4. D. MiR-93 mimics regulate CD274 expression in M-MDSC of 
KPC mice. Representative flow cytometry for M-MDSC (green) and G-MDSC (purple) in the peripheral blood (PB) and pancreatic tumor 
(KPC) (upper). Sorted M-MDSC from PB were treated ex vivo with control or miR-93 mimics and analyzed for the expression of CD274. 
Representative flow cytometry (lower left) and quantification (lower right); n=3, *p<0.05. E. Effect of OTX015 (500nM; 72 hours) on the 
target genes cd274 and cxcl12 in myeloid and fibroblastoid stromal cells, n=6, * p<0.05.
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growth, and disease progression as shown for multiple 
myeloma cells [30]. Specifically, Nalm-6 pre-B acute 
lymphoblastic leukemia cells (ALL) have been reported 
to metastasize to CXCL12+ vascular niches in the BM 
due to their pronounced sensitivity to the chemoattractive 
cues of CXCL12 [31]. Using CXCL12-sensitive Nalm-6 
cells to detect changes in the BM CXCL12 gradient, we 
demonstrated that the regulation of CXCL12 in the BM 
stromal niche via the miR-25-93-106b cluster also affected 
homing, and thereby metastasis. These findings should 
have implications for other cancers as CXCL12/CXCR4 
signaling has been demonstrated as a driving mechanism 
for many cancers including pancreatic cancer [3, 4].
Next, we found that miR-93/106b also regulated 
CD274, e.g. in response to irradiation. The latter is not only 
used as total body irradiation for BM transplantation but also 
as radiotherapy for the treatment of primary and metastatic 
cancer. Paradoxically, our data suggest that ionizing 
irradiation may induce multiple resistance mechanisms 
that could facilitate tumor relapse, e.g. via enhancing 
CXCL12 and also CD274/CD279 (PD-L1/PD-1) signaling, 
thus limiting anti-tumor immunity [32, 33]. Specifically, 
cancer cells and MDSCs in the tumor microenvironment 
upregulate PD-L1 (CD274) to suppress anti-tumor 
immunity by inhibition of the T cell-mediated cytotoxicity 
[32, 33]. MDSCs are categorized as a group of immature 
monocytic and granulocytic myeloid-derived suppressor 
cells, in which hypoxia has been demonstrated to upregulate 
CD274 via hypoxia-inducible factor-1 (HIF-1). Blockade 
of CD274 diminished MDSC-mediated T cell suppression 
by modulation of the MDSC-produced cytokines [34]. 
To date, however, only a few studies have investigated 
the regulation of CD274 by miR, e.g. a study showing 
the role of miR-513 in modulating CD274 in human 
cholangiocytes [35]. Another study determined that miR-
197 is downregulated in chemoresistant non-small-cell 
lung cancer, and restoring miR-197 using miR mimics re-
sensitizes CD274high drug-resistant cells to chemotherapy 
[36]. Our data now demonstrate that expression of CD274 
in MDSC is regulated by the miR-25-93-106b cluster 
and its expression can be reduced significantly by the 
use of miR-93 mimics. It is important to note, however, 
that the contribution of CD274 expression on non-tumor 
cells to inhibit the anti-tumor response has at least been 
questioned[37] and recent studies in pre-clinical lung 
cancer models also suggested a more dominant role for 
cancer cell-derived CD274 [38]. It has been reported 
that CD274 is induced on murine melanoma cells upon 
communication with BM-derived CD11b+ cells BM-
derived immune cells [39].
Consistently, we found that medium conditioned by 
macrophages as the most abundant and pro-tumorigenic 
cell population in the tumor microenvironment [20], 
further enhanced CD274 expression in pancreatic cancer 
cells. We used pancreatic cancer cells as a role model of 
a disease with very strong immunosuppressive properties 
[40]. While many human cancers such as advanced 
melanoma showed impressive response to treatment with 
immune checkpoint inhibitors, patients with pancreatic 
cancer did not respond to immunological checkpoint 
antagonists, although cancer cell-specific CD8+ T 
cells were certainly present [41, 42]. However, after 
depletion of fibroblast activation protein (FAP)+ stromal 
cells producing CXCL12 in the tumor, immune control 
of PDAC growth could be achieved by the synergistic 
action of a CXCL12 receptor chemokine (C-X-C motif) 
4 inhibitor and anti-PD-L1 [43], an approach that is 
currently tested in a clinical Phase 2 trial for patients with 
metastatic pancreatic cancer. Here, our data suggest that 
expression of CD274 in pancreatic cancer cells and the 
surrounding immunosuppressive MDSC is inhibited by 
miR-93 and 106b. Therefore, our work identifies a crucial 
dual role for the miR-25-93-106b cluster in the regulation 
of both CXCL12 and CD274, thereby mimicking the 
synergistic action of CXCL12 and PD-L1 inhibition, and 
suggests therapeutic potential for therapy-resistant PDAC.
While the clinical translation of our finding based 
on the use of miR mimics to modulate CXCL12 and 
PD-L1 may be considered challenging, we have been 
able to enhance the expression of the miR-25-93-106b 
cluster using a clinical grade BET inhibitor, i.e. OTX015. 
This molecule reversibly binds the BET proteins BRD2, 
BRD3, BRD4, and BRDT, and prevents protein-protein 
interactions between BET proteins and acetylated histones 
and transcription factors. BET inhibitors attenuate cell 
growth and survival in several hematologic cancer models 
[44], but also in pancreatic cancer models [45], at least in 
part through the down-regulation of the critical oncogene 
MYC. However, the mode of action of BET inhibitors 
is multifaceted, cell type-dependent, and may involve 
a broad signaling and transcriptional rewiring of both 
tumor cells and the tumor stroma. Here we demonstrate 
for the first time that BET inhibitors are able to induce 
miR-93/106b in the stromal microenvironment that could 
be important for developing more effective combination 
treatments. Indeed, pancreatic cancer patients have been 
shown to be mostly resistant to PD-1 inhibition [46] and 
also BET inhibitors alone only transiently slowed tumor 
progression [47]. Based on the data presented herein, 
it will be interesting to now study the effects of PD-1 
inhibitors in combination with BET inhibitors in order to 
enhance the efficacy of checkpoint targeting.
MATERIALS AND METHODS
miRNA expression array
Total RNA was fluorescently labeled (Sham: Hy3; 
ischemia: Hy5) and hybridized to topic-defined PIQOR™ 
miRXplore Microarrays. Fluorescence was detected using 
a laser scanner from Agilent (Agilent Technologies). Our 
data represent the average values for 10 mice per group. 
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Data were subsequently ranked for average miRNA 
expression.
Flow cytometry
CD45– BM stromal cells were stained using anti-
mouse CD45-APC, CD45-FITC, CD45-PE, SCA-1-
PE (all BD Biosciences), CD140a (PDGFRa)-PECy7, 
and CD274-APC (both Biolegend). Myeloid cells were 
identified using CD11b-FITC (Biolegend) or CD11b-
PerCP-Cy5.5 (eBiosciences). MDSC were stained using 
CD11b-PerCP Cy5.5, Gr-1-PECy7 (eBiosciences), k and 
LyC-Alexa700 (Biolegend). For intracellular staining of 
CXCL12, cells were fixed with 4% paraformaldehyde, 
permeabilized in 0.1% Triton X (PBS-T), and stained 
with SDF-1-Fluorescein (R&D; IC350F, 1:10). For 
surface staining, antibodies were used at 1:50 in PBS for 
10min at room temperature and live cells negative for 
4’,6-Diamidino-2-phenylindol (DAPI; Sigma: 1μg/ml) 
were analyzed on the Fortessa or sorted with the ARIA II 
cell sorter (both BD).
RT-qPCR
Total RNA was isolated using QIAzol (Qiagen) and 
complementary DNA synthesized (for miRNA: NCode 
VILO miRNA cDNA synthesis kit; for non-miRNA: 
SuperScript VILO cDNA synthesis kit; both Invitrogen). 
MiR qPCR was performed using Express SYBR 
GreenER Supermix with premixed ROX (Invitrogen). 
SNORD95 was used as housekeeping gene for miR to 
normalize the Ct values (ΔCt), and relative expression was 
calculated using the 2-ΔΔCt method. Primers for miRNA 
qPCR for miR-25, miR-93, miR-106b, and SNORD95 
were purchased from Qiagen. For mRNA, QPCR was 
performed using PerfeCTa SYBR Green fastMix low 
Rox (Quanta Biosciences). Ct values were normalized to 
housekeeping genes such as HPRT, GAPDH, and Rps29 
(ΔCt), and relative expression was calculated using 
the 2-ΔΔCt method. The list of primers can be found in 
Supplementary Table 1.
In vivo experiments
Unilateral hind limb ischemia was induced by 
ligating the deep and superficial femoral artery with 
an electrocoagulator and validated using this In Vivo 
Imaging System IVIS-200 as described previously [48]. 
Myocardial infarctions were created by ligating the 
left anterior descending coronary artery. Scar size was 
quantified with ImageJ (NIH) using the midline method 
[49]. BM transplantation was carried out as previously 
described [50]. Briefly, recipient mice were irradiated with 
12Gy total body irradiation given in a single dose. Twenty-
four hours later, donor BM cells were intravenously 
administered by retro-orbital plexus injection. Mice 
constitutively expressing the far-red fluorescent protein 
Katushka were a kind gift of Sagrario Ortega (CNIO). For 
in vivo homing analysis, recipient mice were irradiated 
with 12Gy and treated with 80mg/kg CyclosporineA i.p. 
24h prior to the i.v. injection of 2x106 DiD-labeled donor 
cells [51]. Mice were sacrificed 6 or 48hrs later for flow 
cytometry of the BM [52]. All animal procedures were 
conducted in accordance to the 3Rs and were approved 
by the Institute’s Institutional Animal Care and Use 
Committee (CBA 68_2013 & CBA 25_2009 & PPL70-
8129).
miRNA inhibitors/mimics
MiR were inhibited using mmu-miR-93 antagomiRs 
(5’ → 3’: C*U*A CCU GCA CGA ACA GCA C*U*U 
*U*G, *phosphorothiates), mmu-miR-106b antagomiRs 
(A*U*C UGC ACU GUC AGC AC*U *U*U*A), 
or scrambled control (A*A*G *C*AC GCG CGU 
UGA GA*A *U*U*G) at 1.2µM (Biospring). MiR-
93, miR-106b mimics, or control mimics were used at 
200pmol/24-well). To induce miR106 knockdown, cells 
were transduced with a lentiviral construct for miR106b 
knockdown identified by expression of GFP (miR106b 
OFF GFP; LentimiRa-Off-mmu-miR-106b-5p Vector, 
Applied Biological Materials, Richmond, Canada).
Invasion/migration assays
First, CD45– WT BM cells or MSC were seeded 
into the lower wells in in 200μl RPMI medium + 2% 
B-27 supplement (Thermo Fisher Scientific), grown to 
80% confluency, and treated with antagomirs for 6hrs. 
BD Matrigel™-precoated inserts, 8μm pore size, were 
seeded with 5x104 BM or Nalm-6 cells using the same 
medium in the absence or presence of AMD3465 (10μM; 
Tocris Bioscience), inserted into above wells, and allowed 
to transmigrate for 42hrs. Transmigrated cells were fixed 
with 4 % paraformaldehyde, stained with DAPI (1:2,500), 
imaged by confocal microscopy, and images were 
analyzed using Imaris 8.0 software (Bitplane) applying the 
Imaris spot detection algorithm to assign a spot for each 
fluorescent intensity of a single nucleus. For migration 
studies, cells were labeled with the far red cell tracker 
DiD (Vybrant™ cell-labeling solution; ThermoFisher 
Scientific). 6-channel μ-slide (μ-slide VI 0.4; ibidi) were 
pre-filled with complete RPMI + 2% FCS + 10μM 
cyclosporine A (Sigma, to prevent xenogeneic response). 
One side was loaded with femora and tibiae fragments 
from mice irradiated with 12Gy, whereas the other side 
was loaded with 104 DiD+ Nalm-6 cells. The number of 
cells that passed beyond mid-way of the channel by 20h 
were scored as migrating cells. In a modification of this 
assay, we used 1x105 miR-106b OFF PDAC cells with or 
without CXCL12 CRISPR/Cas9 knockout as target cells 
and allowed 1x103 (low number) Nalm-6 cells or 1x105 
(high number) Nalm-6 cells to migrate towards the target 
cells for 20h.
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Primary PDAC cultures
Pancreatic tumors were obtained from murine 
pancreatic cancer models (Ela-KRAS and KPC) or patient-
derived xenografts as described previously[53]. Tumors 
were homogenized using a gentleMACS dissociator 
followed by enzymatic digestion with collagenase P for 
15min at 37°C, and cultured in DMEM + 10% FCS. 
Outgrowing epithelial clones were then further expanded 
to heterogeneous cancer cell cultures. Stromal cells were 
mechanically removed by cell scraping and cultured 
separately. For some experiments, we required murine 
stromal cell rich primary PDAC cultures and used the 
stroma rich CKT111 PDAC cultures with mesenchymal 
features. Culture under low adhesion conditions to 
enrich for cancer stem cells and human pancreatic cancer 
xenografts have been described previously [54]. In some 
experiments, cells were treated with the BET inhibitor 
OTX015 (Cayman Chemicals; 500nM). To culture spheres 
enriched in cancer stem cells, cells were re-suspended in 
1X DMEM/F-12 (Gibco™) supplemented with 20ng/ml 
FGF-2 (CellGS), 0.4% Amphotericin B, 1% Penicillin/
Streptomycin, 2% B27 supplement (Gibco™) and 
200mM of L-glutamine (Gibco™). A cell suspension of 
10,000cells/ml was then prepared and distributed into 
ultra-low attachment surface flasks (Corning, NY, NY) for 
one week. Prior to use, spheres were filtered (40 µM for 
human spheres, 20 µM cell strainer for murine spheres).
Generation of Cxcl12 knock-out cells
Cxcl12 knock-out clones were generated using 
CRISPR/Cas9 gene editing as previously described 
[55]. Briefly, 4 sgRNAs targeting exon 2 of mouse 
Cxcl12 were cloned into the lentiCRISPR v2 backbone 
(a gift from Feng Zhang; Addgene plasmid # 52961) 
and transfected into CKT111 cells. Single cell-derived 
clones were generated following puromycin selection and 
Cxcl12 knock-out was validated by ELISA for murine 
CXCL12 (Duoset, R&D) from cell culture supernatants. 
We used the following targeting sgRNA sequences: 
sg#1 TGAGCTACCGATGCCCCTGC; sg#2 CAGA 
TGCTTGACGTTGGCTC; sg#3 GATTTTCAGATGC 
TTGACGT; sg#4 TGACGTTGGCTCTGGCGATG.
3’UTR luciferase reporter assays
The 3’UTR-Cxcl12 Gaussia luciferase reporter 
construct (2μg per 24-well) and a control 3’UTR-reporter 
construct (all from Genecopoeia) were transfected into 
HEK293T cells using Lipofectamine (Invitrogen). Co-
transfection per 24-well (containing 5x104 cells) was 
performed with double-stranded miR-93 mimic, miR-106b 
mimic, or control mimic (Sigma; all at 200pmol/24-well). 
In addition, a Renilla Luciferase reporter construct was 
used as a transfection efficiency control for normalization 
(0.6 μg per 24-well). Secreted Gaussia luciferase activity 
was measured using the Secrete-Pair® Dual Luminescence 
Assay Kit (Genecopoeia). Renilla luciferase activity was 
measured using the Dual-Luciferase® Reporter Assay 
System (Promega).
Immunostaining
For the live confocal microscopy of migrated DiD+ 
cells, nuclei were counterstained with Hoechst (Hoechst 
33342; 1μg/ml), and the bones (sternum) placed into an 
Attofluor ™ cell chamber (Life Technologies) for viewing 
live specimens prior to analysis using a Leica SP5 
confocal microscope for the presence of DiD+ Nalm-6 
cells. For the confocal analysis of CXCL12 expression in 
the BM of WT and Mir-25-93-106b-KO bone fragments, 
we fixed the bones in 4% paraformaldehyde for 10min 
at room temperature, washed twice with PBS, incubated 
in PBS + 0.1% Triton X (PBS-T) for 15min at room 
temperature, followed by incubation of the CXCL12-
Fluorescein (R&D; IC350F) antibody 1:10 in PBS-T for 
30min at room temperature. Nuclei were counterstained 
with DAPI (Sigma, 1μg/ml) prior to analysis using a Leica 
SP5 confocal microscope.
Immunohistochemistry
Bone fragments from sternum were harvested, 
fixed in 10% neutral buffered formalin, decalcified, 
and then paraffin embedded. Immunohistochemical 
staining on 2.5μM sections was carried out using the 
Ventana Discovery XT system (Roche). Sections were 
deparaffinized, hydrated, and loaded on the Discovery 
XT. Antigen retrieval was performed using citrate buffer 
solution. Endogenous peroxidases were quenched using 
H2O2 reagent (Ventana). Primary antibodies against 
myeloperoxidase and factor VIII (both Dako, rabbit 
polyclonal, diluted 1:300), and CD31 (Abcam; rabbit 
polyclonal, diluted 1:50), and CD274 (Cell Signaling; 
diluted 1:150, rabbit mAb recognizing endogenous levels 
of total PD-L1 protein), were incubated for 20min and 
detected using an anti-rabbit secondary antibody and the 
ChromaMap DAB detection kit (Ventana). Tissues were 
counterstained with hematoxylin and image analysis 
was performed using Pannoramic Viewer Software 
(3DHISTECH).
miR in situ hybridization (ISH)
ISH for miR-106b was performed as previously 
described [56]. Briefly, FFPE sections at 5μm thickness 
were deparaffinised, rehydrated and boiled with 0.01M 
sodium citrate buffer (pH 6) for 10 minutes. The samples 
were then prehybridised for 20 minutes at 48oC, before 
incubating with 25nM DIG-labelled LNA oligonucleotide 
probe (Exiqon) for 1 hour at 48oC. Samples were blocked 
with 5% sheep serum for 1 hour at room temperature, 
then incubated with alkaline phosphatase-conjugated 
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anti-DIG antibody (1:1,000) overnight at 4oC. Slides 
were developed with NBT/BCIP for 30min, then lightly 
counterstained with methyl green before dehydration and 
mounting.
Statistical analysis
Unless stated otherwise, results are expressed as 
the means ± SEM. Statistical analyzes were performed 
with SPSS 22.0 (San Diego, CA) comparing continuous 
variables by non-parametrical Mann-Whitney U and 
Kruskal-Wallis tests. Statistical analysis of Kaplan-Meier 
curves is performed by the log-rank test. The significance 
is given as p<0.05.
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